The Incyte Ingenuity Awards in GVHDTM

Supporting the graft-versus-host disease (GVHD) community

The 2025 Incyte Ingenuity Awards in GVHD™ recipients have been selected! Find out about the award-winning projects.

Announcing the 2025 Incyte Ingenuity Awards in GVHD Recipients: The Ohio State University Comprehensive Cancer Center and Circadian OS!

We are pleased to announce that The Ohio State University Comprehensive Cancer Center and Circadian OS, in partnership with Mount Sinai's Light and Health Research Center, are the recipients of the 2025 Incyte Ingenuity Awards in GVHD! These proposals demonstrate a commitment to addressing the specific needs of the GVHD community.

The Ohio State University (OSU) Comprehensive Cancer Center logo

The Ohio State University (OSU) Comprehensive Cancer Center was awarded $50,000 to implement its project, Identifying Genitourinary GVHD Diagnostic and Prognostic Qualitative Factors. This initiative aims to address the current limitations of clinical care and management of genitourinary (GU) GVHD, an under-recognized manifestation of chronic GVHD. In collaboration with OSU's James Oncology Rehabilitation, the project will pilot the development of a questionnaire for screening and longitudinal symptom assessments of post-transplant patients. The goal of this project is to prevent delays in identification of GU GVHD and to further refine and expand access to specialized care to improve the wellbeing, physical functionality and quality of life for people with GVHD.

Circadian OS logo

Circadian OS was awarded $35,000 to implement its project, RhythmCare: A Personalized Circadian Light Program for GVHD Patients. In collaboration with Mount Sinai's Light and Health Research Center, the project aims to establish a program for people with GVHD to teach the benefits of how to utilize light exposure, structured routines and circadian principles to enhance physical wellbeing. Circadian OS will co-create a tablet-based toolkit specific for those with GVHD that will feature support guides and personalized daily schedules, both revolving around circadian light exposure to help ameliorate symptoms. The goal of this program is to help support the wellbeing of those with GVHD and improve quality of life.

Learn more about the 2025 award-winning projects.

See the recipients

What Are the Incyte Ingenuity Awards in GVHD?

Watch the following video to hear the inaugural award recipient explain how devastating GVHD can be for patients, and how the Incyte Ingenuity Awards in GVHD program aims to support people living with GVHD, as well as their caregivers and physicians.

Areej E-Jawahri, M.D., Associate Director, Cancer Outcomes Research and Education Program, Director, Bone Marrow Transplant Survivorship Program, Associate Professor of Medicine, Massachusetts General Hospital, provides information on the impact of GVHD and how the Incyte Ingenuity Awards in GVHD aims to support those impacted.

The Incyte Ingenuity Award program is not currently accepting applications.

Applications will reopen in the first half of 2026.

In the meantime, please see below for general program information about the 2026 award cycle.

Eligibility

Eligibility Information

The following groups and individuals are eligible to apply for the Incyte Ingenuity Awards in GVHD:

Image of hands holding heart

Non-profit 501(c)(3), patient, policy and caregiver organizations

Image of caduceus

Healthcare providers, junior faculty, and/or other clinical and research staff of healthcare organizations*

Image of two people

Individuals or other companies collaborating with these organizations and institutions**

Programs must be independent of any ongoing activities, with the exception of considerably expanding an existing program. Additionally, programs cannot include indirect costs with the proposed budget. To be eligible, you and your organization must be US based (including Washington DC and Puerto Rico).

*Applications must be submitted in the name of an institution, not on behalf of an individual.

**Individuals or other companies interested in applying must partner with either a non-profit organization or a healthcare facility (i.e., hospitals, academic research centers, etc.) to be eligible.

Applications will be disqualified if:

  • Focus is on a particular therapeutic agent, translational research, or clinical research that is interventional in nature
  • Program is based on an existing initiative, with no evidence of ingenuity
  • Organization is improperly identified as a 501(c)(3) organization
  • Application is submitted by a healthcare professional as an individual (individuals will need to partner with a not-for-profit or other organization to be considered)
  • Defined scope does not serve or plan to address a specific need of the GVHD community
  • Request in funding exceeds 25 percent of an organization's overall annual budget and/or includes indirect costs
  • Application is submitted by an employee of Incyte, Real Chemistry, and/or other vendors, or members of the immediate family of any such persons
  • Program is duplicated, with multiple copies of an application submitted by the same organization
  • Program exceeds the maximum application limit per organization (more than five)
  • Program includes monetary support, gifts, or other items of monetary value to patients, either directly or indirectly
  • Applicant and/or organization are not based in the United States

Incyte reserves the right to modify the eligibility requirements at any time.

Have additional questions? Check out our FAQ page.

Peg Squier, Group Vice President, U.S. Medical Affairs, Incyte, provides an overview of the program, outlines eligibility requirements and the necessary steps in submitting an application.

Meet the Judges

Meet the Judges

Meet our 2025 Incyte Ingenuity Awards in GVHD judging panel!

Image of Marti Cowden

Marti Cowden

Marti Cowden is a community volunteer, caregiver and mother. She serves as the Executive Vice President of the Meredith A. Cowden Foundation, a non-profit organization that bears her daughter’s name. Marti co-founded the Meredith A. Cowden Foundation with her husband while being a full-time caregiver to Meredith, who was diagnosed with Acute Myelogenous Leukemia in 2001. The organization works to increase education and support for patients, as well as promote research and novel treatments for GVHD. Marti plays a key role in managing the Foundation's daily operations, fundraising efforts and strategic planning. Marti has held a variety of roles throughout her diverse career, from travel agent to President of a local women’s service organization. She continues to provide support for Meredith’s chronic GVHD and is an admirable advocate in the GVHD community. Marti's efforts have made the Meredith A. Cowden Foundation's GVHD National Symposium a leading event for sharing the latest advances in chronic GVHD treatment and management.

More
Less
Image of Christina Ferraro

Christina Ferraro, CNP

Christina Ferraro is an accomplished healthcare professional with extensive expertise in hematology and medical oncology. She serves as the Outpatient Advanced Practice Provider Manager at the Cleveland Clinic Cancer Institute, as well as the Director of Survivorship and is a nurse practitioner in the Transplantation and Cellular Therapy and Apheresis programs at the Cleveland Clinic. Prior to her current position, Christina made significant contributions as a nurse and nurse practitioner at the Cleveland Clinic, where she specialized in survivorship, late-effects and graft-versus-host disease in blood and marrow transplant patients. Christina holds a master’s degree in Family Practice Nurse Practitioner from Kent State University and a bachelor’s degree in nursing from The Ohio State University.

More
Less
Image of Dr Pooja Khandelwa

Pooja Khandelwal, MD

Dr Pooja Khandelwal is a member of the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center and serves as Associate Professor in the UC Department of Pediatrics. She graduated from Kasturba Medical College in Manipal, India, completed her residency at the University of Arizona College of Medicine, and completed her fellowship at Cincinnati Children's Hospital Medical Center. Dr Khandelwal is a pediatric hematologist-oncologist specializing in bone marrow transplantation for hemoglobinopathies, malignancies and metabolic disorders. She also runs a multidisciplinary clinic focused on taking care of children with chronic GVHD. Her research interests focus on restoring and maintaining intestinal homeostasis in patients during the peri-transplant period. Her goal is to reduce the incidence of GVHD by using a variety of approaches, such as administration of specific nutritional compounds and modification of the intestinal microbiome. Dr Khandelwal and her organization were also recipients of the 2022 Incyte Ingenuity Awards in GVHD. Learn more about her award-winning project.

More
Less
Image of Catherine Lee

Catherine Lee, MD

Dr Catherine Lee is an Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Center and serves as Associate Professor, Division of Hematology and Oncology at the University of Washington School of Medicine. She is a medical oncologist with clinical expertise in blood and marrow transplantation and cellular therapy. Dr Lee dedicates her clinical and research efforts to treating late complications of blood and marrow transplantation, with a particular focus on chronic GVHD. Her research portfolio includes design of clinical trials to mitigate cGVHD and other late effects of stem cell transplantation, implementing interventions to improve access to high-quality post-transplant care, and optimizing quality of life.

More
Less
Image of Susan Stewart

Susan Stewart

Susan Stewart is the Founder and Executive Director of the Blood and Marrow Transplant Information Network (BMT InfoNet). BMT InfoNet is a not-for-profit organization that provides information and support services to bone marrow, peripheral blood stem cell and cord blood transplant (hematopoietic cell transplant) recipients before, during and after treatment. At BMT InfoNet, Stewart oversees all operations, and as a transplant survivor herself, she brings great insight and perspective to her work. She is widely considered a vital resource to the entire transplant community. Stewart also authored Bone Marrow and Blood Stem Cell Transplants: A Guide for Patients; Autologous Stem Cell Transplants: A Handbook for Patients; Graft-versus-Host Disease: What to Know, What to Do; and CAR T-Cell Therapy: What to Expect Before, During and After – all of which are used extensively by transplant centers throughout the U.S. and Canada to educate patients. Stewart holds a degree in Sociology/Urban Affairs from Northwestern University.

More
Less
alert icon

Incyte will not provide any advice or input during the judging process, and all decisions made by the judging panel are made independently and are final. These judges will receive compensation for their services from Incyte, based on fair market value.

Judging Criteria

Judging Criteria

Our independent judging panel will consider the following criteria when evaluating each award application:

Checkmark iconDoes the applicant meet the eligibility requirements?

Handshake iconDid the applicant collaborate with any other organizations to optimize the success of the initiative?

Documents iconDoes the application contain all of the necessary details and supporting documents?

Puzzle piece iconDoes the proposal exhibit a thoughtful, creative and innovative approach to address a specific need within the GVHD community?

Stopwatch iconCan the proposal be completed within the one-year time frame?

Target iconDoes the proposal demonstrate a clear purpose and rationale?

Dollar sign iconDoes the proposal include a realistic and appropriate budget?

Upward pointing arrow iconDoes the proposal have clear and measurable outcomes? Does it follow the SMART (specific, measurable, achievable, realistic, timely) methodology for setting goals?

Incyte reserves the right to change the judging criteria at any time.